Form 8-K - Current report:
SEC Accession No. 0001404644-24-000109
Filing Date
2024-11-21
Accepted
2024-11-21 16:01:15
Documents
13
Period of Report
2024-11-20
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K ngne-20241120.htm   iXBRL 8-K 23267
  Complete submission text file 0001404644-24-000109.txt   149598

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngne-20241120.xsd EX-101.SCH 1788
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngne-20241120_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngne-20241120_pre.xml EX-101.PRE 13050
15 EXTRACTED XBRL INSTANCE DOCUMENT ngne-20241120_htm.xml XML 2802
Mailing Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011
Business Address 535 W 24TH STREET 5TH FLOOR NEW YORK NY 10011 (877) 237-5020
Neurogene Inc. (Filer) CIK: 0001404644 (see all company filings)

EIN.: 980542593 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 241484167
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)